Henri Spronk

Chief Executive Officer
Coagulation Profile, Maastricht, The Netherlands
Maastricht, Limburg, Netherlands

Presentation(s):

• OC 31.3 - Phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of VMX-C001 in healthy subjects

  Monday, June 26, 2023
  11:15 – 11:30 ET